DY
FATE icon

Dowling & Yahnke’s Fate Therapeutics FATE Stock Holding History

Dowling & Yahnke’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$687K Hold
30,640
– – 0.03% 253
2022
Q2 		$759K Hold
30,640
– – 0.04% 240
2022
Q1 		$1.19M Hold
30,640
– – 0.05% 215
2021
Q4 		$1.79M Sell
30,640
-250
-0.8% -$14.2K 0.09% 178
2021
Q3 		$1.83M Buy
30,890
+250
+0.8% +$19.6K 0.1% 174
2021
Q2 		$2.66M Buy
+30,640
New +$2.47M 0.15% 146

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Dowling & Yahnke's FATE Position: Q3 2022 in Review

Dowling & Yahnke held its Fate Therapeutics (FATE) position steady in Q3 2022 at 30,640 shares worth $687K. The position accounts for 0.03% of the portfolio, ranked #253.

Dowling & Yahnke first reported a position in FATE in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.66M in Q2 2021. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Dowling & Yahnke held 30,640 shares of Fate Therapeutics worth $687K as of Q3 2022.
  • Dowling & Yahnke left its Fate Therapeutics share count unchanged in Q3 2022.
  • Fate Therapeutics made up 0.03% of Dowling & Yahnke's portfolio in Q3 2022, its #253 holding.
  • Dowling & Yahnke first reported a position in Fate Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • Dowling & Yahnke's Fate Therapeutics position peaked at $2.66M in Q2 2021.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.